PledPharma AB (publ) announced that the company’s global phase III program, POLAR, has been accepted for a poster presentation during the Gastrointestinal (GI) Cancers Symposium in January 17-19 in San Francisco. The symposium is one of the most prominent within the field of gastrointestinal (GI) cancers globally with ASCO (American Association of Clinical Oncology) as one of the co-sponsors.